University spinout royalties are the cash side of the deal that lets a company built on university research use that research. The equity side gets the attention. The royalty side is where the money quietly leaves, every quarter, for as long as the patents live and often past the day the company is sold.
This guide lists the five payments that travel under the word "royalties", puts the published rates from the UK, Denmark, the Netherlands, Australia and the US side by side, explains the three mechanics that decide what a rate really costs, and ends with the terms worth negotiating. We write it from the venture-builder side of the table, where we pay these fees and hold the patents behind them.
What university spinout royalties actually include
A founder reads "royalty" and pictures one percentage. A tech transfer office reads it and sees a menu. One investor and lawyer's account of spinout deals lists the economic rights universities commonly seek: upfront royalties, milestone payments, running royalties, sublicensing fees and fee reimbursements, usually alongside an equity stake that often lands around 5 percent.
The CASRAI guide to licence structure breaks the same menu into its parts. Each has a different job.
Signing fee and patent cost reimbursement
A one-time payment on signing, partly to recover patent costs the university has already spent and partly to prove the licensee is serious. The reimbursement can be the larger number. In the University of Melbourne's published life-sciences example, the university pays provisional and PCT fees in the first year, the start-up prepays national phase costs at least 14 days before each filing deadline, and historical costs are repaid in equal instalments over three years.
Minimum annual royalty or technology access fee
A guaranteed floor the company pays whether or not it sells anything. CASRAI explains the purpose: it protects the institution from an exclusive licensee that stops commercialising the technology without formally terminating the licence. The timing is negotiable. The NIH start-up model licence sets a US$5,000 payment within 60 days of signing but defers the first minimum annual royalty to the third anniversary. Denmark's national standard licensing models charge nothing in years one and two, then a technology access fee of DKK 15,000 in year three, DKK 30,000 in year four and DKK 50,000 from year five, with the fee deducted from the royalty owed that year.
Running royalty on net sales
The percentage everyone argues about. It is paid on net sales of products that use the licensed IP, usually quarterly. CASRAI notes that the definition of net sales, meaning which deductions for returns, freight and taxes are allowed before the percentage applies, is itself heavily negotiated.
Milestone payments
Fixed sums triggered by events: first patient dosed, regulatory approval, first commercial sale. They are common in life sciences, where development runs for years before any sale.
Sublicence income share
If the spinout licenses the technology onward, the university takes a share of what it collects. In pharma, this clause can outweigh every other number in the agreement. More on that below.
Published royalty rates for spinouts
There is no global rate. There are a handful of transparent systems, and reading them together gives a founder a real range. For the commercial benchmarks a licensee would pay outside the university context, EX IX has compiled patent licensing royalty rates by industry.
UK: the USIT royalty windows
The University Spin-out Investment Terms guide, agreed by the leading UK tech transfer offices and VCs, recommends a royalty window of 0.5 to 2 percent for know-how or very early technologies, 2 to 5 percent for more progressed technologies, and above 5 percent for advanced ones.
Its anonymised case studies show the full package. In one, the company repaid roughly £50k of patent costs, agreed milestone payments totalling £1.0 million up to first regulatory approval, and a net royalty of 3.0 percent. In another, the company paid a c. £50k signing fee, royalties of 0.5 to 1.5 percent depending on patent coverage, triggered only once cumulative net sales passed £25 million, plus success milestones of 0.5 to 2 percent of valuation on IPO or exit, capped at £5 million.
Denmark: rates by sector
The Danish standard models publish their ranges outright: life science 1 to 3 percent under the royalty model or 0.5 to 2 percent under the milestone model, deep tech 1 to 4 percent, software and AI 2 to 6 percent, market-ready industrial technology 1 to 6 percent. A royalty rate tool starts from a base rate of 3 percent (2 percent for life science) and adjusts for technology strength and market size. The spinout covers all patent costs from day one.
Netherlands: rates by maturity
The Dutch national IP deal term principles tie the rate to readiness: up to 5 percent for technologies at TRL 3 to 4, typically above 5 percent for later-stage technologies with stronger IP positions or clinical-stage assets. The package also includes a substantially higher percentage on sublicence income, a minimum annual royalty whose first instalment doubles as the upfront fee, and optional milestones.
Worked templates from Australia and the UK investor side
Melbourne's life-sciences example sets 3 percent of net product sales and 10 percent of sublicence income, with the sales royalty halved for any product no longer covered by a valid patent claim. A UK university template reviewed by DSW Ventures carried royalties of 0.5 to 2.5 percent depending on technology maturity and margin, and 5 to 15 percent on licence income.
| System | Running royalty | Sublicence share | Early cash |
|---|---|---|---|
| UK, USIT windows | 0.5 to 2% early, 2 to 5% progressed, over 5% advanced | Tiered, decreasing | Signing fee c. £50k in case studies |
| Denmark, standard models | 1 to 4% deep tech, 2 to 6% software and AI | 15% | None until year 3, then DKK 15k to 50k a year |
| Netherlands, national principles | Up to 5% at TRL 3 to 4, above 5% later | Substantially higher than sales rate | Minimum annual royalty, first payment upfront |
| Melbourne example | 3% of net sales, halved outside valid claim | 10% | Patent cost repayment over 3 years |
| UK template, DSW review | 0.5 to 2.5% | 5 to 15% | £50k signing fee |
Three mechanics that matter more than the headline rate
Two spinouts can sign the same 2 percent and pay very different amounts. The difference sits in three clauses.
The base: net sales, not profit
DSW's point is blunt. Royalties take the first bite out of revenues, because they are calculated on sales rather than profit. A 2 percent royalty on a product with 20 percent gross margin is a tenth of the gross profit, before any salary is paid.
The term: royalties that survive the exit
In the template DSW reviewed, both royalty streams survive past exit until the patents expire. An acquirer inherits them and prices them in. Melbourne defines its royalty term as the later of patent expiry, 20 years after first commercial sale, or the end of regulatory exclusivity. Read the term clause with the exit in mind, because it will be read that way by whoever buys you. The related spinout transfer fee is then charged on a price already reduced by the royalty holdback.
Stacking caps and valid-claim step-downs
Deep-tech products often need two or more licences from the same university. Denmark's Model B1 spinout licence handles this with a maximum stacking royalty: if two or more agreements from the licensor are needed to make and sell a product, the combined royalty on that product cannot exceed the cap on the cover sheet. A published Copenhagen Model B2 example lists that cap at 2.5 percent. USIT likewise expects floors for bundled or stacked IP. The second protection is the valid-claim step-down in the Melbourne example: once a product falls outside a granted claim and relies only on know-how, the rate halves.
Sublicence income: the clause that paid for Xtandi
Sublicence income is where university spinout royalties stop being a rounding error. The Licensing Executives Society analysis of sublicense income describes three structures. An allocation gives the university a set share of every payment the licensee receives from a sublicensee. A tiered allocation uses a lower share before commercialisation and a higher one after, often starting negotiations at the 25 percent Goldscheider figure. A pass-through keeps the university's running royalty on the sublicensee's sales at the same rate it would have earned on the spinout's own sales.
The case that made the clause famous is Xtandi. UCLA licensed a series of compounds to Medivation with milestones totalling US$2.8 million, a 4 percent royalty passed through to sublicensee sales, and 10 percent of sublicensing income. Medivation then partnered with Astellas for US$110 million upfront, up to US$335 million in development milestones and up to US$320 million in sales milestones, and the parties ended up in dispute over whether sales milestones counted as royalties on sales or as sublicensing income. LESI's arithmetic: 10 percent of a billion-dollar partnering deal is US$100 million.
The lesson for a founder is to define the terms now. USIT says licensees are commonly limited to one tier of sublicensing, must pay head licence royalties and milestones whether they or the sublicensee hit them, and should get tiered, decreasing percentages on sublicence receipts to reward investment. Denmark fixes the split at 85 percent to the company and 15 percent to the university.
What royalties cost: the investor's worked example
DSW's scenario makes the stack concrete. A therapeutics spinout signs a £50k signing fee, which for a company funded by the £250k Seed EIS maximum is 20 percent of its first round. At exit the acquirer expects £20 million of annual revenue, pays 2.5 percent royalties on it for a remaining 12-year patent life, and holds back £6 million of a £100 million price to cover them. Add the exit fee and the university's diluted shares, and the total university take is £14.6 million, close to half of it from add-ons rather than equity.
The same post records the other failure mode. DSW walked away from a spinout whose university insisted on a meaningful royalty stream while investors were still funding losses. No other VC stepped in. The royalty stream it protected was zero.
For scale, the UK Independent Review of University Spin-out Companies found UK universities earned £244 million from licensing IP and £86 million from share sales in 2021/22, together 2.1 percent of research expenditure, with the six largest research universities taking around half of all licensing income and both streams driven by a small number of large successes. Royalties are a lottery ticket for the university. They should not be a tax on the company that has not yet won it.
Trading royalties against equity and upfront cash
Royalties, equity and signing fees are one price expressed three ways, and the published models say so.
- Cash for a lower rate. Under the Danish models, an upfront payment reduces the royalty rate by 25 percent or lowers the annual access fee, though never below the agreed minimum rate.
- Equity for a lower rate. Denmark's mixed model halves the royalty and grants the university equity equal to 1.5 times the original rate, between 3 and 5 percent, non-dilutive until the spinout has raised DKK 20 million. That non-dilution term is the same one examined in university spinout anti-dilution.
- Lower fees for more equity. USIT notes a spin-out usually wants to avoid early licence fees and prefers reduced royalties or milestones, with the university's equity at the higher end of its range to compensate. How that range is set is the subject of university spinout equity split.
- Founder-friendly fixed rates. The Russell Group briefing on spinouts cites Imperial's Founders Choice track, where academic founders keep up to 95 percent of founding equity in exchange for low fixed royalty rates.
- A buy-off at exit. The Dutch principles let a spinout that takes the option to acquire the IP buy off the royalty obligation for a FRAND fee negotiated at exit; Denmark offers a fixed buy-out price agreed up front.
Every one of these trades is easier to make before the first investor term sheet, which is one reason how long a university license takes matters.
Seven terms to negotiate
- Defer the minimum. The NIH model starts minimum annual royalties on the third anniversary; Denmark charges nothing for two years. Ask for the same runway.
- Put a threshold on the running royalty. The USIT case study triggers royalties only after £25 million of cumulative net sales. A threshold lets you reinvest early revenue.
- Write in the valid-claim step-down. If a product no longer sits inside a granted claim, the rate should fall, as Melbourne's 50 percent reduction does.
- Cap stacking. If you will need more than one licence from the university, insist on a maximum stacking royalty on the cover sheet.
- Tier the sublicence share and define the income. Lower before commercialisation, higher after, and a definition that says exactly which milestones count, so you never relive the Xtandi dispute.
- Price the buy-off now. A FRAND negotiation at exit is a negotiation with no leverage. A fixed buy-out price is a number you can raise against.
- Refuse the full menu. DSW lists six add-ons a template can carry: signing fee, annual fees, milestones, royalties, windfall payments and a charge for assignment. One or two of them is a price. All six is a company that cannot be funded, which is the problem university spinout funding has to solve.
How we look at it as a venture builder
At EX EPIC we finance, patent and deploy breakthrough science that would otherwise stay in the lab, with a EUR 160M+ capital track record behind the portfolio. Our patent marketplace EX IX launched with 24 patent families filed, so we sit on both sides of this clause: as the licensee paying a royalty and as the holder setting one.
Our view: a royalty is a fair price for the risk a university took on an invention before anyone else would. It should be paid on sales that use the claims, not on everything the company does, at a rate that steps down as the patent ages, and with a date on which it ends. A royalty with no threshold, no cap and no exit is not a licence term. It is a permanent shareholder that never gets diluted.
FAQ
What is a typical royalty rate for a university spinout?
Published guidance clusters in low single digits. The UK USIT guide gives windows of 0.5 to 2 percent for early technologies, 2 to 5 percent for progressed ones and above 5 percent for advanced ones. Denmark's models set 1 to 4 percent for deep tech and 2 to 6 percent for software and AI.
Do spinouts pay royalties before they have revenue?
Running royalties, no. Minimum annual royalties or access fees, often yes, but they can be deferred: the NIH model starts them on the third anniversary and Denmark charges DKK 15,000 in year three rising to DKK 50,000 from year five, credited against royalties owed.
What is a minimum annual royalty for?
It guarantees the university a floor regardless of sales and protects it from an exclusive licensee that stops commercialising the technology without terminating the licence, so the IP is not left idle.
How much sublicence income does the university take?
Published figures run from 5 to 15 percent in one UK template, 10 percent in the Melbourne example and 15 percent in Denmark, with 25 percent often the starting point once a product is commercialised.
Can a spinout buy out its royalty obligation?
Sometimes. The Dutch national principles give a spinout the option to buy off royalties for a FRAND fee at exit, and Denmark's Model B lets the parties fix a buy-out price in the original agreement.